BioCentury | Aug 28, 2019
Clinical News

Aug. 28 Clinical Quick Takes: InDex's cobitolimod hits Phase IIb endpoint in UC; plus AstraZeneca and Mitsubishi

...Europe. If FDA approves it, AZ would owe a $150 million milestone to shareholders of Pearl Therapeutics Inc....
...Wong, Staff Writer cobitolimod (DIMS 0150, kappaproct) levodopa/carbidopa (ND0612L, ND0612) PT010 AstraZeneca plc InDex Pharmaceuticals Holding AB Mitsubishi Tanabe Pharma Corp. NeuroDerm Ltd. Pearl Therapeutics Inc. Parkinson's...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...postmenopausal women at high risk of fracture AstraZeneca plc (LSE:AZN; NYSE:AZN) Gained in acquition of Pearl Therapeutics Inc....
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

...deal through Avillion to co-develop PT027, a fixed-dose combination of budesonide and albuterol, with the Pearl Therapeutics Inc....
BioCentury | Feb 10, 2017
Company News

Management tracks

...Immuno-oncology company Harpoon Therapeutics Inc. (Cambridge, Mass.) named William Picht CFO. He was CFO at Pearl Therapeutics Inc....
BioCentury | May 30, 2016
Finance

It takes a village

...drag on the portfolio," said Schwab. The major wins came from biotech: Relypsa Inc. and Pearl Therapeutics Inc....
BioCentury | May 2, 2016
Clinical News

Bevespi Aerosphere glycopyrrolate/formoterol fumarate regulatory update

...has not yet set a price. AZ gained Bevespi Aerosphere via its 2013 acquisition of Pearl Therapeutics Inc....
BioCentury | Apr 27, 2016
Company News

FDA approves AZ's Bevespi Aerosphere for COPD

...placebo, glycopyrrolate and formoterol fumarate individually. AZ gained Bevespi Aerosphere via its 2013 acquisition of Pearl Therapeutics Inc....
BioCentury | Jun 15, 2015
Finance

Products, hold the platform

...M&A, and an additional five companies went public. The biggest win was respiratory disease company Pearl Therapeutics Inc....
BioCentury | May 14, 2015
Targets & Mechanisms

Sense and sensibility

...developed at later stages of clinical testing. Lechuga-Ballesteros is principal scientist in R&D at the Pearl Therapeutics Inc....
BioCentury | Mar 19, 2015
Clinical News

AstraZeneca meets in Phase III COPD trials

...agonist (LABA), delivered via a hydrofluoroalkane metered-dose inhaler. AZ gained PT003 via its acquisition of Pearl Therapeutics Inc....
Items per page:
1 - 10 of 59
BioCentury | Aug 28, 2019
Clinical News

Aug. 28 Clinical Quick Takes: InDex's cobitolimod hits Phase IIb endpoint in UC; plus AstraZeneca and Mitsubishi

...Europe. If FDA approves it, AZ would owe a $150 million milestone to shareholders of Pearl Therapeutics Inc....
...Wong, Staff Writer cobitolimod (DIMS 0150, kappaproct) levodopa/carbidopa (ND0612L, ND0612) PT010 AstraZeneca plc InDex Pharmaceuticals Holding AB Mitsubishi Tanabe Pharma Corp. NeuroDerm Ltd. Pearl Therapeutics Inc. Parkinson's...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...postmenopausal women at high risk of fracture AstraZeneca plc (LSE:AZN; NYSE:AZN) Gained in acquition of Pearl Therapeutics Inc....
BioCentury | Jul 13, 2018
Finance

Curating Abingworth

...deal through Avillion to co-develop PT027, a fixed-dose combination of budesonide and albuterol, with the Pearl Therapeutics Inc....
BioCentury | Feb 10, 2017
Company News

Management tracks

...Immuno-oncology company Harpoon Therapeutics Inc. (Cambridge, Mass.) named William Picht CFO. He was CFO at Pearl Therapeutics Inc....
BioCentury | May 30, 2016
Finance

It takes a village

...drag on the portfolio," said Schwab. The major wins came from biotech: Relypsa Inc. and Pearl Therapeutics Inc....
BioCentury | May 2, 2016
Clinical News

Bevespi Aerosphere glycopyrrolate/formoterol fumarate regulatory update

...has not yet set a price. AZ gained Bevespi Aerosphere via its 2013 acquisition of Pearl Therapeutics Inc....
BioCentury | Apr 27, 2016
Company News

FDA approves AZ's Bevespi Aerosphere for COPD

...placebo, glycopyrrolate and formoterol fumarate individually. AZ gained Bevespi Aerosphere via its 2013 acquisition of Pearl Therapeutics Inc....
BioCentury | Jun 15, 2015
Finance

Products, hold the platform

...M&A, and an additional five companies went public. The biggest win was respiratory disease company Pearl Therapeutics Inc....
BioCentury | May 14, 2015
Targets & Mechanisms

Sense and sensibility

...developed at later stages of clinical testing. Lechuga-Ballesteros is principal scientist in R&D at the Pearl Therapeutics Inc....
BioCentury | Mar 19, 2015
Clinical News

AstraZeneca meets in Phase III COPD trials

...agonist (LABA), delivered via a hydrofluoroalkane metered-dose inhaler. AZ gained PT003 via its acquisition of Pearl Therapeutics Inc....
Items per page:
1 - 10 of 59